{"id":10275,"date":"2021-04-12T16:47:38","date_gmt":"2021-04-12T15:47:38","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=10275"},"modified":"2021-05-20T10:27:05","modified_gmt":"2021-05-20T09:27:05","slug":"aptorum-group-essai-clinique-de-phase-1-sur-lals-4-un-medicament-destine-a-traiter-les-infections-a-staphylocoque-dore","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/aptorum-group-essai-clinique-de-phase-1-sur-lals-4-un-medicament-destine-a-traiter-les-infections-a-staphylocoque-dore\/","title":{"rendered":"Aptorum Group : essai clinique de Phase 1 sur l’ALS-4, un m\u00e9dicament destin\u00e9 \u00e0 traiter les infections \u00e0 staphylocoque dor\u00e9"},"content":{"rendered":"\n

Aptorum Group annonce avoir administr\u00e9 une dose au premier sujet humain dans le cadre d’un essai clinique de Phase 1 sur l’ALS-4, un m\u00e9dicament \u00e0 petite mol\u00e9cule de premi\u00e8re cat\u00e9gorie destin\u00e9 \u00e0 traiter les infections \u00e0 staphylocoque dor\u00e9 (Staphylococcus aureus), notamment le staphylocoque dor\u00e9 r\u00e9sistant \u00e0 la m\u00e9thicilline (SARM)<\/strong><\/p>\n\n\n\n

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (\u00ab Aptorum Group \u00bb ou \u00ab Aptorum \u00bb), une soci\u00e9t\u00e9 biopharmaceutique ax\u00e9e sur les nouvelles technologies dont le ciblage des maladies infectieuses, a annonc\u00e9 avoir administr\u00e9 une dose au premier sujet humain dans le cadre de son essai clinique de Phase 1 \u00e9valuant l’ALS-4, un m\u00e9dicament \u00e0 petite mol\u00e9cule administr\u00e9 oralement pour le traitement des infections \u00e0 staphylocoque dor\u00e9 (Staphylococcus aureus)<\/em>, notamment le SARM.<\/p>\n\n\n\n

Le premier essai clinique de Phase 1 sur des humains est un essai randomis\u00e9, en double aveugle, contr\u00f4l\u00e9 par plac\u00e9bo, et \u00e0 dose unique croissante ou \u00e0 doses multiples croissantes, destin\u00e9 \u00e0 \u00e9valuer l’innocuit\u00e9, la tol\u00e9rance et le profil pharmacocin\u00e9tique de l’ALS-4 administr\u00e9 oralement chez des volontaires adultes sains, hommes et femmes. L’\u00e9tude pr\u00e9voit de recruter jusqu’\u00e0 48 volontaires sains pour la cohorte qui se verra administrer une dose unique croissante et 24 volontaires sains pour celle qui recevra une dose multiple croissante, respectivement. Le recrutement pour la premi\u00e8re cohorte recevant la dose unique croissante est d\u00e9sormais achev\u00e9. Nous continuons de recruter des participants pour les autres cohortes de l’essai.<\/p>\n\n\n\n

Le Dr Clark Cheng, responsable m\u00e9dical et directeur ex\u00e9cutif d’Aptorum Group, a d\u00e9clar\u00e9: \u00ab L’administration d’une dose au premier sujet humain dans le cadre de l’essai clinique sur l’ALS-4 constitue une \u00e9tape importante dans la mise en oeuvre d’un nouveau m\u00e9canisme d’action de traitement potentiel des infections \u00e0 staphylocoque dor\u00e9<\/em>, notamment le SARM. Depuis 1958, date de l’homologation initiale de la vancomycine, un seul agent additionnel, la daptomycine (dont les deux antibiotiques constituent un traitement administr\u00e9 principalement par voie intraveineuse n\u00e9cessitant l’hospitalisation des patients pendant le traitement), a \u00e9t\u00e9 autoris\u00e9 pour le traitement de la bact\u00e9ri\u00e9mie au SARM. Les taux d’\u00e9chec clinique et de mortalit\u00e9 pour cette maladie infectieuse majeure demeurent cependant dangereusement \u00e9lev\u00e9s. Soumis aux r\u00e9sultats du prochain essai clinique, nous estimons que l’ALS-4 pourrait constituer un nouvel agent anti-infectieux potentiel, \u00e0 l’approche anti-virulence unique, capable de g\u00e9n\u00e9rer des r\u00e9sultats positifs pour ces patients. Nous sommes tr\u00e8s enthousiastes d’entreprendre cet essai clinique de Phase 1 et impatients de le compl\u00e9ter le plus rapidement possible \u00bb.<\/p>\n\n\n\n

\u00c0 propos de la mol\u00e9cule ALS-4<\/strong><\/p>\n\n\n\n

Faisant partie d’Acticule, la plateforme de maladies infectieuses d’Aptorum Group, l’ALS-4 est une petite mol\u00e9cule in\u00e9dite de premi\u00e8re cat\u00e9gorie, administr\u00e9e oralement et d\u00e9velopp\u00e9e dans le cadre d’une approche antivirulence de ciblage du staphylocoque dor\u00e9<\/em> et du SARM. L’ALS-4 cible les propri\u00e9t\u00e9s antimicrobiennes de la bact\u00e9rie. Il semble qu’elle rend la bact\u00e9rie extr\u00eamement sensible \u00e0 la clairance immunitaire de l’h\u00f4te. L’ALS-4 devrait pouvoir \u00eatre administr\u00e9 seul, et \u00e9galement combin\u00e9 \u00e0 d’autres antibiotiques existants tels la vancomycine.<\/p>\n\n\n\n

\u00c0 propos d\u2019Aptorum Group<\/strong><\/p>\n\n\n\n

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) est une soci\u00e9t\u00e9 pharmaceutique qui se consacre \u00e0 la d\u00e9couverte, au d\u00e9veloppement et \u00e0 la commercialisation d’agents th\u00e9rapeutiques destin\u00e9s \u00e0 traiter des pathologies \u00e0 besoins m\u00e9dicaux encore non satisfaits, en particulier les maladies infectieuses et les cancers (y compris les indications orphelines en oncologie). Le portefeuille de projets d’Aptorum s’est \u00e9galement enrichi gr\u00e2ce \u00e0 (i) la cr\u00e9ation de plateformes de d\u00e9couverte de m\u00e9dicaments donnant lieu \u00e0 la mise au point de nouveaux agents th\u00e9rapeutiques \u00e0 travers des programmes tels que le contr\u00f4le syst\u00e9matique des mol\u00e9cules pharmaceutiques d\u00e9j\u00e0 approuv\u00e9es, et gr\u00e2ce \u00e0 la plateforme de recherche bas\u00e9e sur le microbiome dans le cadre du traitement des maladies m\u00e9taboliques; et gr\u00e2ce au d\u00e9veloppement conjoint, avec Accelerate Technologies Pte Ltd, branche commerciale de l’Agence singapourienne pour la Science, la technologie et la recherche (“A*STAR”), d’une technologie de diagnostic mol\u00e9culaire novatrice d’identification et de d\u00e9tection rapides d’un pathog\u00e8ne (“RPIDD”).<\/p>\n\n\n\n

Outre notre objectif principal susmentionn\u00e9, nous menons \u00e9galement des projets th\u00e9rapeutiques dans le domaine de la neurologie, de la gastroent\u00e9rologie, des troubles du m\u00e9tabolisme, de la sant\u00e9 f\u00e9minine et d’autres domaines pathologiques. Certains de nos projets sont \u00e9galement ax\u00e9s sur les compl\u00e9ments naturels destin\u00e9s aux femmes m\u00e9nopaus\u00e9es et qui en subissent les sympt\u00f4mes.<\/p>\n\n\n\n

Pour de plus amples informations \u00e0 propos d’Aptorum Group, veuillez visiter\u00a0www.aptorumgroup.com<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

Aptorum Group annonce avoir administr\u00e9 une dose au premier sujet humain dans le cadre d’un essai clinique de Phase 1 sur l’ALS-4, un m\u00e9dicament \u00e0 petite mol\u00e9cule de premi\u00e8re cat\u00e9gorie destin\u00e9 \u00e0 traiter les infections \u00e0 staphylocoque dor\u00e9 (Staphylococcus aureus), notamment le staphylocoque dor\u00e9 r\u00e9sistant \u00e0 la m\u00e9thicilline (SARM) Aptorum Group Limited (Nasdaq: APM, Euronext […]<\/p>\n","protected":false},"author":139,"featured_media":10287,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[31],"tags":[],"acf":[],"yoast_head":"\nAptorum Group : essai clinique de Phase 1 sur l'ALS-4, un m\u00e9dicament destin\u00e9 \u00e0 traiter les infections \u00e0 staphylocoque dor\u00e9 - French\u00a0National ANTIBIOTIC RESISTANCE Portal<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/aptorum-group-essai-clinique-de-phase-1-sur-lals-4-un-medicament-destine-a-traiter-les-infections-a-staphylocoque-dore\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aptorum Group : essai clinique de Phase 1 sur l'ALS-4, un m\u00e9dicament destin\u00e9 \u00e0 traiter les infections \u00e0 staphylocoque dor\u00e9 - French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/aptorum-group-essai-clinique-de-phase-1-sur-lals-4-un-medicament-destine-a-traiter-les-infections-a-staphylocoque-dore\/\" \/>\n<meta property=\"og:site_name\" content=\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-12T15:47:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-05-20T09:27:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/04\/Aureus.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"828\" \/>\n\t<meta property=\"og:image:height\" content=\"601\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c9milie Noguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c9milie Noguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/aptorum-group-essai-clinique-de-phase-1-sur-lals-4-un-medicament-destine-a-traiter-les-infections-a-staphylocoque-dore\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/aptorum-group-essai-clinique-de-phase-1-sur-lals-4-un-medicament-destine-a-traiter-les-infections-a-staphylocoque-dore\/\"},\"author\":{\"name\":\"\u00c9milie Noguez\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\"},\"headline\":\"Aptorum Group : essai clinique de Phase 1 sur l’ALS-4, un m\u00e9dicament destin\u00e9 \u00e0 traiter les infections \u00e0 staphylocoque dor\u00e9\",\"datePublished\":\"2021-04-12T15:47:38+00:00\",\"dateModified\":\"2021-05-20T09:27:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/aptorum-group-essai-clinique-de-phase-1-sur-lals-4-un-medicament-destine-a-traiter-les-infections-a-staphylocoque-dore\/\"},\"wordCount\":769,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/aptorum-group-essai-clinique-de-phase-1-sur-lals-4-un-medicament-destine-a-traiter-les-infections-a-staphylocoque-dore\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/04\/Aureus.jpg\",\"articleSection\":[\"Actualit\u00e9s\"],\"inLanguage\":\"en-GB\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/aptorum-group-essai-clinique-de-phase-1-sur-lals-4-un-medicament-destine-a-traiter-les-infections-a-staphylocoque-dore\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/aptorum-group-essai-clinique-de-phase-1-sur-lals-4-un-medicament-destine-a-traiter-les-infections-a-staphylocoque-dore\/\",\"name\":\"Aptorum Group : essai clinique de Phase 1 sur l'ALS-4, un m\u00e9dicament destin\u00e9 \u00e0 traiter les infections \u00e0 staphylocoque dor\u00e9 - French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/aptorum-group-essai-clinique-de-phase-1-sur-lals-4-un-medicament-destine-a-traiter-les-infections-a-staphylocoque-dore\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/aptorum-group-essai-clinique-de-phase-1-sur-lals-4-un-medicament-destine-a-traiter-les-infections-a-staphylocoque-dore\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/04\/Aureus.jpg\",\"datePublished\":\"2021-04-12T15:47:38+00:00\",\"dateModified\":\"2021-05-20T09:27:05+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/aptorum-group-essai-clinique-de-phase-1-sur-lals-4-un-medicament-destine-a-traiter-les-infections-a-staphylocoque-dore\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/aptorum-group-essai-clinique-de-phase-1-sur-lals-4-un-medicament-destine-a-traiter-les-infections-a-staphylocoque-dore\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/aptorum-group-essai-clinique-de-phase-1-sur-lals-4-un-medicament-destine-a-traiter-les-infections-a-staphylocoque-dore\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/04\/Aureus.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/04\/Aureus.jpg\",\"width\":828,\"height\":601,\"caption\":\"Cr\u00e9dit : Pixabay\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/aptorum-group-essai-clinique-de-phase-1-sur-lals-4-un-medicament-destine-a-traiter-les-infections-a-staphylocoque-dore\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Practical info & communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Aptorum Group : essai clinique de Phase 1 sur l’ALS-4, un m\u00e9dicament destin\u00e9 \u00e0 traiter les infections \u00e0 staphylocoque dor\u00e9\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"name\":\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"description\":\"INSERM - From science to health\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\",\"name\":\"\u00c9milie Noguez\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aptorum Group : essai clinique de Phase 1 sur l'ALS-4, un m\u00e9dicament destin\u00e9 \u00e0 traiter les infections \u00e0 staphylocoque dor\u00e9 - French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/aptorum-group-essai-clinique-de-phase-1-sur-lals-4-un-medicament-destine-a-traiter-les-infections-a-staphylocoque-dore\/","og_locale":"en_GB","og_type":"article","og_title":"Aptorum Group : essai clinique de Phase 1 sur l'ALS-4, un m\u00e9dicament destin\u00e9 \u00e0 traiter les infections \u00e0 staphylocoque dor\u00e9 - French\u00a0National ANTIBIOTIC RESISTANCE Portal","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/aptorum-group-essai-clinique-de-phase-1-sur-lals-4-un-medicament-destine-a-traiter-les-infections-a-staphylocoque-dore\/","og_site_name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","article_published_time":"2021-04-12T15:47:38+00:00","article_modified_time":"2021-05-20T09:27:05+00:00","og_image":[{"width":828,"height":601,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/04\/Aureus.jpg","type":"image\/jpeg"}],"author":"\u00c9milie Noguez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"\u00c9milie Noguez","Estimated reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/aptorum-group-essai-clinique-de-phase-1-sur-lals-4-un-medicament-destine-a-traiter-les-infections-a-staphylocoque-dore\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/aptorum-group-essai-clinique-de-phase-1-sur-lals-4-un-medicament-destine-a-traiter-les-infections-a-staphylocoque-dore\/"},"author":{"name":"\u00c9milie Noguez","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3"},"headline":"Aptorum Group : essai clinique de Phase 1 sur l’ALS-4, un m\u00e9dicament destin\u00e9 \u00e0 traiter les infections \u00e0 staphylocoque dor\u00e9","datePublished":"2021-04-12T15:47:38+00:00","dateModified":"2021-05-20T09:27:05+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/aptorum-group-essai-clinique-de-phase-1-sur-lals-4-un-medicament-destine-a-traiter-les-infections-a-staphylocoque-dore\/"},"wordCount":769,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/aptorum-group-essai-clinique-de-phase-1-sur-lals-4-un-medicament-destine-a-traiter-les-infections-a-staphylocoque-dore\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/04\/Aureus.jpg","articleSection":["Actualit\u00e9s"],"inLanguage":"en-GB"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/aptorum-group-essai-clinique-de-phase-1-sur-lals-4-un-medicament-destine-a-traiter-les-infections-a-staphylocoque-dore\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/aptorum-group-essai-clinique-de-phase-1-sur-lals-4-un-medicament-destine-a-traiter-les-infections-a-staphylocoque-dore\/","name":"Aptorum Group : essai clinique de Phase 1 sur l'ALS-4, un m\u00e9dicament destin\u00e9 \u00e0 traiter les infections \u00e0 staphylocoque dor\u00e9 - French\u00a0National ANTIBIOTIC RESISTANCE Portal","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/aptorum-group-essai-clinique-de-phase-1-sur-lals-4-un-medicament-destine-a-traiter-les-infections-a-staphylocoque-dore\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/aptorum-group-essai-clinique-de-phase-1-sur-lals-4-un-medicament-destine-a-traiter-les-infections-a-staphylocoque-dore\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/04\/Aureus.jpg","datePublished":"2021-04-12T15:47:38+00:00","dateModified":"2021-05-20T09:27:05+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/aptorum-group-essai-clinique-de-phase-1-sur-lals-4-un-medicament-destine-a-traiter-les-infections-a-staphylocoque-dore\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/aptorum-group-essai-clinique-de-phase-1-sur-lals-4-un-medicament-destine-a-traiter-les-infections-a-staphylocoque-dore\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/aptorum-group-essai-clinique-de-phase-1-sur-lals-4-un-medicament-destine-a-traiter-les-infections-a-staphylocoque-dore\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/04\/Aureus.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/04\/Aureus.jpg","width":828,"height":601,"caption":"Cr\u00e9dit : Pixabay"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/aptorum-group-essai-clinique-de-phase-1-sur-lals-4-un-medicament-destine-a-traiter-les-infections-a-staphylocoque-dore\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Practical info & communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/"},{"@type":"ListItem","position":3,"name":"News","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/"},{"@type":"ListItem","position":4,"name":"Aptorum Group : essai clinique de Phase 1 sur l’ALS-4, un m\u00e9dicament destin\u00e9 \u00e0 traiter les infections \u00e0 staphylocoque dor\u00e9"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"INSERM - From science to health","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3","name":"\u00c9milie Noguez"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-28 00:51:24","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/10275"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/comments?post=10275"}],"version-history":[{"count":5,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/10275\/revisions"}],"predecessor-version":[{"id":10289,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/10275\/revisions\/10289"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media\/10287"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media?parent=10275"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/categories?post=10275"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/tags?post=10275"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}